Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$17.48 +2.7%	$17.66	$13.53 ▼ $35.25	$1.76B	2.09	1.49 million shs	1.24 million shs
CRSP CRISPR Therapeutics	$48.20 -0.9%	$39.69	$30.04 ▼ $63.68	$4.16B	1.75	2.37 million shs	2.81 million shs
EDIT Editas Medicine	$2.23 +1.1%	$1.78	$0.91 ▼ $6.05	$186.26M	2.1	2.57 million shs	1.34 million shs
NTLA Intellia Therapeutics	$9.78 +4.3%	$8.59	$5.90 ▼ $28.18	$1.01B	2.15	2.93 million shs	4.20 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+1.25%	+1.80%	+8.07%	-3.57%	-27.40%
CRSP CRISPR Therapeutics	+2.42%	+6.78%	+34.96%	+46.77%	-9.94%
EDIT Editas Medicine	-3.51%	+4.76%	+26.80%	+94.69%	-52.89%
NTLA Intellia Therapeutics	-1.88%	+1.63%	+34.19%	+40.84%	-58.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.3172 of 5 stars	3.5	1.0	0.0	2.2	2.5	0.6
CRSP CRISPR Therapeutics	2.9278 of 5 stars	4.3	1.0	0.0	2.0	2.5	0.6
EDIT Editas Medicine	4.2334 of 5 stars	3.2	3.0	4.2	2.5	2.5	0.6
NTLA Intellia Therapeutics	4.6182 of 5 stars	4.3	3.0	4.7	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	178.95% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	48.85% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	111.24% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	241.05% Upside

Current Analyst Ratings Breakdown

Latest NTLA, BEAM, CRSP, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	27.67	N/A	N/A	$8.86 per share	1.97
CRSP CRISPR Therapeutics	$37.31M	111.57	N/A	N/A	$22.64 per share	2.13
EDIT Editas Medicine	$32.31M	5.76	N/A	N/A	$1.63 per share	1.37
NTLA Intellia Therapeutics	$57.88M	17.51	N/A	N/A	$8.56 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)

Latest NTLA, BEAM, CRSP, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
CRSP CRISPR Therapeutics	N/A	15.64	15.64
EDIT Editas Medicine	N/A	3.08	3.08
NTLA Intellia Therapeutics	N/A	4.90	4.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
EDIT Editas Medicine	71.90%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CRSP CRISPR Therapeutics	4.10%
EDIT Editas Medicine	1.90%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.82 million	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable

NTLA, BEAM, CRSP, and EDIT Headlines

Recent News About These Companies

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by Brokerages

June 29 at 3:22 AM | marketbeat.com

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Nasdaq

June 27, 2025 | nasdaq.com

NTLA - Intellia Therapeutics Inc Chart - Morningstar

June 26, 2025 | morningstar.comM

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

June 25, 2025 | zacks.com

Intellia Therapeutics, Inc. (NTLA) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

NTLA Intellia Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.4% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

June 21, 2025 | finance.yahoo.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - What's Next?

June 20, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 19, 2025 | finance.yahoo.com

Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

June 18, 2025 | theglobeandmail.com

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 17, 2025 | msn.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's Why

June 17, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from Wedbush

June 16, 2025 | marketbeat.com

6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...

June 16, 2025 | benzinga.com

Intellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC Wainwright

June 16, 2025 | marketbeat.com

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

June 15, 2025 | globenewswire.com

Brokers Issue Forecasts for NTLA FY2026 Earnings

June 10, 2025 | marketbeat.com

Intellia Therapeutics Inc.

June 9, 2025 | barrons.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?

June 6, 2025 | marketbeat.com

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA, BEAM, CRSP, and EDIT Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$17.48 +0.47 (+2.74%)

As of 03:44 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$48.20 -0.44 (-0.90%)

As of 03:44 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Editas Medicine NASDAQ:EDIT

$2.22 +0.03 (+1.14%)

As of 03:43 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$9.78 +0.40 (+4.31%)

As of 03:43 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time